IRCT20230801058996N6招募中1 期
Safety and efficacy of combination therapy with rituximab and activated allogeneic haplo-identical natural killer cells in relapsed/refractory non-Hodgkin's lymphoma patients
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 years 至 80 years（—）
- 性别
- All
入选标准
- •Patients with non-Hodgkin's lymphomas with the origin of B lymphocytes confirmed based on WHO criteria and clinical and paraclinical evidence
- •Patients with non-response or insufficient response to the first stage of treatment based on clinical and paraclinical evidence
- •Patients with disease recurrence
- •Patients with ECOG index of 0-2
排除标准
- •Non-Hodgkin's B-cell lymphomas Patients with clinical and paraclinical full recovery
- •Non-Hodgkin's B-cell lymphomas Patients with clinical and paraclinical appropriate response to the first stage of treatment
研究者
相似试验
已完成
不适用
Efficacy and safety of combination therapy with vildagliptin and nateglinide in type 2 diabetes.JPRN-UMIN000004010Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine40
已完成
不适用
The efficacy and safety of combination therapy of adoptive immunotherapy with chemotherapy for advanced pancreatic cancerJPRN-UMIN000011177Tokai University School of Medicine20
尚未招募
不适用
IDA for OnchocerciasisOnchocerciasisPACTR201906665550709Washington University in St. Louis300
进行中（未招募）
1 期
Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis - Rituximab and Leflunomide in RAEUCTR2005-004582-41-GBniversity of Leeds15
进行中（未招募）
不适用
COMET TrialJPRN-jRCTs031180210Yokote Koutaro60